Heartflow Beats With 57% Revenue Growth, Lifts 2026 Outlook to $262-264M
HTFL has more than doubled off its 52-week low of $20.13 on elevated volume (2.1× avg).
Summary
Heartflow posted Q3 2026 revenue of $72.9 million, up 57% year-over-year, with U.S. revenue up 60% to $67.9 million. Gross margin expanded to 83.6% from 76.5% a year ago, and the non-GAAP net loss shrank to $2.7 million, or $0.03 per share, from $13.2 million, or $0.27 per share. Management raised full-year 2026 revenue guidance to $262-264 million (roughly 49-50% growth) from $246-250 million, and lifted non-GAAP gross margin guidance to about 82.5% from 82%. This is the third consecutive quarter of accelerating growth, following Q2's 48% growth to $64.1 million reported in the August 10-Q. The company ended the quarter with $253.0 million in cash and investments, and adjusted EBITDA loss narrowed to $3.6 million from $9.8 million. The stock is trading near its 52-week high, so the raised guidance is the key test of whether that run holds.
At the time of this announcement, HTFL was trading at $61.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $20.13 to $60.66. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.